|
"I'M PERSONALLY extremely embarrassed by where the share price is at the moment," was how Pete Smith began his presentation for drug researcher Alchemia. Alchemia chairman Mel Bridges said he was frustrated the market did not "see the true value" in the business, which had received positive broker coverage. Kann mich denen beiden nur anschließen wenn Alchemia die Zulassung im 4Q 08 erhält, halte ich kurse zwischen 3-5A$ auf Sicht von 12-18 Monate für realistisch . ----------- Arixtra wächst weiter und mit der Zulassung für die ACS (acute coronary syndromes)Indikation im 1H 08(USA) dürften die Umsätze noch stärker steigen . GlaxoSmithKline 1Q : Arixtra sales US US$38 ($US32m) up 19% Europe US$28m (US$22m) up 27% RoW US$4m (US$4m) gsk's comments: New growth drivers Arixtra, for deep vein thrombosis and pulmonary embolism, delivered strong growth with sales up 70% to £35 million. Sales grew in Europe (up 33% to £14 million) following approval last year for the treatment of specific acute coronary syndromes (ACS). In the USA, GSK is in on-going discussions with the FDA regarding a potential ACS indication. -------- Drug recalled amid contamination fears Sean Parnell | April 23, 2008 A SECOND blood-thinning drug was last night recalled by Australian health authorities amid a worldwide contamination scandal their American counterparts fear may have contributed to dozens of deaths in the US alone. A month after AstraZeneca recalled 100,000 doses of heparinised saline in Australia, the Therapeutic Goods Administration last night ordered the recall of five batches of the Sanofi-Aventis drug Clexane as testing of related blood-thinning products continued. "To date, in Australia, there have been no reports of adverse events of the type reported in the US associated with heparin products," the TGA said in a statement. "Nevertheless, the TGA has decided to quarantine the affected batches of Clexane so no patients are put at undue risk at this time." Heparin, which is derived from pig and cow intestines, and its derivatives are commonly used in hospitals to prevent clots forming in dialysis and other equipment and in patients themselves. But a contaminant, oversulfated chondroitin sulfate, has been found in products produced in China, leading to drugs being withdrawn in several countries. The US Food and Drug Administration has been investigating hundreds of adverse reactions to heparin use and found 81 deaths where those symptons had been seen, though no causal link has been determined. The FDA's Janet Woodcock, who claimed China had conceded heparin produced in the country was contaminanted, said the authority had "now established a mechanism by which we think this contaminant could cause these adverse events". Chinese officials have so far publicly declined to accept responsibility for the contamination. Dr Woodcock said contaminated shipments of the blood thinner had been traced from China to 11 countries, including Australia, but the impact was thought to be greater in the US because of higher doses administered to patients. "Contamination of the heparin supply is a worldwide problem," she said. While other heparin products are still available in Australia, the TGA warned there could be future shortages. www.theaustralian.news.com.au/story/0,25197,23584451-23289,0… |
|
| aus der Diskussion: | Alchemia Limited -- Gelegenheit des Jahres |
| Autor (Datum des Eintrages): | BrauchGeld (27.04.08 14:24:36) |
| Beitrag: | 12 von 83 (ID:33980195) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |